Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859310 | 0.81 | SLC22A12 (0.48) | SLC22A12ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL859590 | 0.78 | ALDH1A1 (0.58) | SLC22A12ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL5958900 | 0.72 | ALDH1A1 (0.67) | HSD11B1ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL10176884 | 0.71 | SLC22A12 (0.49) | SLC22A12 | |
| SCHEMBL10176901 | 0.71 | SLC22A12 (0.46) | SLC22A12 | |
| SCHEMBL13444887 | 0.70 | SLC22A12 (0.53) | SLC22A12ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2677769 | 0.70 | SLC22A12 (0.70) | SLC22A12 | |
| SCHEMBL13325680 | 0.70 | ALDH1A1 (0.47) | ALDH1A1HSD17B10MEN1KMT2AMAPT | |
| SCHEMBL1922935 | 0.69 | SLC22A12 (0.69) | SLC22A12 | |
| SCHEMBL19851098 | 0.67 | SLC22A12 (0.54) | SLC22A12ALDH1A1HSD17B10MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2432774-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2432468-A2 | METHODS OF MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135536-A2 | METHODS OF MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135536-A2 | METHODS OF MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135530-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135530-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | XDH, PON1, RBP4 | SLC22A12 988/4885HSD11B1 884/4885ALDH1A1 188/4885 |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | XDH, PON1, OAT | SLC22A12 1001/4885HSD11B1 1298/4885ALDH1A1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.